Trametinib is a selective and highly potent small molecule inhibitor of MEK1/2 with high oral bioavailability currently approved by the FDA for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations. This evidence concerns the gene MAP2K1 and metastatic melanoma.